Mortality trends in the co-occurrence of urinary tract cancer and diabetes mellitus
-
By
-
Chen-Zhang Ou
-
Yu-Jun Xiong
-
Xiang-Da Meng
-
Tian Lv
-
Lide Song
-
May 22, 2026
-
Clinical Scorecard: Trends in Mortality Associated with Concurrent Urinary Tract Cancer and Diabetes Mellitus
At a Glance
| Category | Detail |
|---|
| Condition | Concurrent Urinary Tract Cancer and Diabetes Mellitus |
| Key Mechanisms | Hyperinsulinemia, insulin resistance, chronic low-grade inflammation, oxidative stress, and accumulation of advanced glycation end products. |
| Target Population | Adults aged ≥25 years with urinary tract cancers and diabetes mellitus. |
| Care Setting | Population-level analysis using national death certificate data. |
Key Highlights
- Mortality increased from 1,566 in 1999 to 4,487 in 2024.
- Age-adjusted mortality rates rose from 0.87 to 1.53 per 100,000.
- Significant mortality surge observed during 2018-2021 (APC 9.93%).
- Men exhibited higher mortality rates than women (AAPC 2.42% vs. 1.00%).
- Non-Hispanic White individuals had the greatest rise in mortality (AAPC 2.51%).
Guideline-Based Recommendations
Diagnosis
- Utilize ICD-10 codes C64–C68 for urinary tract cancers and E10–E14 for diabetes mellitus.
Management
- Integrate prevention and management strategies for patients with concurrent urinary tract cancers and diabetes.
Monitoring & Follow-up
- Monitor demographic and geographic disparities in mortality trends.
Risks
- Consider diabetes-related comorbidities that may limit treatment options.
Patient & Prescribing Data
Adults aged ≥25 years with both urinary tract cancers and diabetes mellitus.
Certain antidiabetic medications may interact with cancer therapies.
Clinical Best Practices
- Evaluate long-term population-level patterns in mortality among individuals with concurrent conditions.
- Address healthcare delivery disruptions impacting cancer screening and diabetes care.
Related Resources & Content
